Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

Improving Health Outcomes in COPD: Hospital-based Strategies for Optimizing Maintenance Therapy and Promoting Patient Self-management


Release date: May 30, 2018
Expiration date: May 30, 2019
Estimated time to complete activity: 1.0 hour(s)

Faculty
 
Gerard Criner, MD, FACP, FACCP
Chair and Professor
Department of Thoracic Medicine and Surgery
Lewis Katz School of Medicine
Temple University
Director
Temple Lung Center
Philadelphia, Pennsylvania
 
Program Overview
 
Hospitals are a critical point of intervention in the care pathway of COPD. Clinicians in this setting must be well-versed in current treatment guidelines, as well as the full spectrum of medications and delivery devices, to provide disease management tailored to the physical and cognitive needs of each patient. Moreover, hospital clinicians also need to be adept at communicating with patients and engaging them in the management of their own disease. Collectively, these measures can significantly reduce symptom severity and risk for future exacerbations, increase physical activity, and improve overall quality of life (QOL) in patients with COPD.
 
Hospital Medicine Summit (HMS) is an innovative, multi-topic educational initiative designed specifically for hospital-based healthcare providers (hospitalists, internal medicine physicians, physician assistants, nurse practitioners, pharmacists, and nurses). With significant changes occurring in the healthcare system, there is an increased demand on hospital-based healthcare providers to provide care that impacts patients not only in the acute setting, but as they transition back into the community and are managed in the chronic-care healthcare system.
 
Target Audience
 
This educational initiative has been designed for hospital-based healthcare providers, including physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists.
 
Learning Objectives
 
Upon completion of this educational activity, participants should be able to:
  • Utilize long-term treatment strategies to reduce hospital readmissions for COPD exacerbations
  • Review the clinical evidence regarding the efficacy and safety of long-acting maintenance regimens for COPD
  • Select medication delivery devices for patients with COPD based upon individual physical and cognitive characteristics
  • Outline a transitional care plan that promotes patient self-management to reduce the risk for future exacerbations and hospital readmissions
Directions to Learner
 
There are no fees for participating and receiving CME credit for this activity. During the period of May 30, 2018 through May 30, 2019, participants must:
  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
 
Media
 
Internet
 
Accreditation Statement
 
  Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
Joint Accreditation Statement
 
  In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integrity Continuing Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 
Credit Designation
 
Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for a total of 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
 
(Universal Activity Number – JA4008162-9999-18-135-H01-P)
Type of Activity: Application 
 
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.
 
Contact Information

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or  hms@integrityce.com.

For information about ACPE or ANCC accreditation of this activity, please contact Post Graduate Institute for Medicine at (303) 799-1930 or inquires@pimed.com.

Disclosure of Conflicts of Interest
 
Integrity Continuing Education and Post Graduate Institute for Medicine require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education and Post Graduate Institute for Medicine for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Integrity Continuing Education and Post Graduate Institute for Medicine are committed to providing learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest or a commercial interest.
 
The following faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
 
Gerard Criner, MD, FACP, FACCP
Consultant: Amirall, AstraZeneca, Avisa, Boehringer Ingelheim, Broncus, CSA Medical, GlaxoSmithKline, Holaira, Lungpacer, Mereo, Pearl, PneumRX, Pulmonx, Third Pole
Research: Department of Defense, National Institutes of Health
Clinical Trials: AstraZeneca, Avisa, Boehringer Ingelheim, Broncus, GlaxoSmithKline, Lungpacer, Mereo, Novartis, PneumRX/BTG, Pulmonx, Yungjin
 
The following planner and manager, Patima Tanapat, PhD, hereby states that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. The PIM planners and managers have nothing to disclose.
 
Disclosure of Unlabeled Use
 
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine and Integrity Continuing Education do not recommend the use of any agent outside of the labeled indications.
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
Privacy Policy
 
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)
 
Minimum System Requirements
 
Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10
Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.
Click here for more information on minimum system requirements.
 
Disclaimer
 
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
 
Provider Statement
 
 
This CME activity is provided by Integrity Continuing Education.
 
This CEU/CNE activity is co-provided by Postgraduate Institute for Medicine and Integrity Continuing Education.
 
Supporter Acknowledgement
 
Supported by an educational grant from Sunovion Pharmaceuticals, Inc.

Fee

$0.00

CE Credits

1.00

Activity Type

  • Knowledge

Target Audience(s)

  • Hospital-based healthcare providers

Accreditation(s)

Accreditation Council for Continuing Medical Ed.
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Support/Credits

 

 

 

 

Activity Number

i705-7

Release Date: May 30, 2018
Credit Expiration Date: May 30, 2019

CE Credits

1.00